Table 4.

Multivariate analysis for overall survival time

		OS time
MN	Variable	HR	95% CI	P value
AML	De novo AML vs t-AML	0.85	0.64–1.12	.25
	Age	1.12	1.01–1.03	.003
	Log WBC	1.11	1.01–1.22	.03
	BM blast percentage	1.25	0.68–2.27	.47
	PS (>1 vs ≤1)	1.40	1.04–1.87	.02
	Cytogenetics (favorable vs poor)	0.34	0.18–0.65	.001
	Cytogenetics (intermediate vs poor)	0.64	0.49–0.85	.002
	HDAC vs non-HDAC	1.53	1.10–2.14	.01
	Biologic agents vs non-HDAC	1.18	0.71–1.99	.52
MDS	Hemoglobin	0.94	0.84–1.05	.28
	Log platelet	0.92	0.79–1.07	.29
	BM blast percentage	1.04	0.99–1.08	.10
	PS*(>1 vs ≤1)	2.08	1.26–3.44	<.01
	Cytogenetics (diploid vs others)	2.01	1.29–3.14	<.01
	IPSS (inter1 vs low)	1.27	0.71–2.29	.42
	IPSS (inter2 vs low)	1.76	0.88–3.52	.11
	IPSS (inter3 vs low	1.98	0.72–5.43	.18

t-AML, therapy-related acute myeloid leukemia; CI, confidence interval; HR, hazard ratio; WBC, white blood cell; BM, bone marrow; OS, overall survival; IPSS, International prognostic score system; and inter, intermediate.; HDAC, high-dose ara-C based regimens.

^*Eastern Cooperative Oncology Group